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Abstract: Chronic kidney disease (CKD) is an increasingly common public health problem that increases the risk of death
because of cardiovascular complications by 2–3 times compared with the general population. This research concerns a prospec-
tive, randomized, double-blind study in patients with CKD undergoing hemodialysis. The participants were assigned to 1 of
2 groups: the study group (group A; 46 patients) received 4 capsules (2.4 g) of omega-3 fatty acids daily during the 12-week
intervention, while patients in the control group (group B; 47 patients) received 4 capsules of paraffin oil. The patients’ general
characteristics, nutritional indicators, renal disease markers and inflammatory markers (C-reactive protein, interleukin (IL)-6,
IL-10, and tumour necrosis factor alpha (TNF-)) were evaluated. No differences were found between the general characteristics
of the patients (P < 0.05), and no differences were shown in the nutritional indicators and markers of kidney disease (P < 0.05).
Patients in group A showed significant decreases in levels of C-reactive protein, IL-6, TNF-, and the IL-10/IL-6 ratio after 12 weeks
of supplementation (P < 0.05). Patients in group B did not show any significant changes in concentrations of inflammatory
markers during the intervention (P < 0.05). In conclusion, oral supplementation with omega-3 fatty acids produces a significant
decrease in the concentrations of inflammation markers in patients with chronic kidney disease on hemodialysis.
Novelty
• Oral supplementation with omega-3 fatty acids produced significant decreases in the concentrations of inflammation markers.
• This supplementation could be given to patients with uremic syndrome and coronary heart disease to reduce cardiovascular risk.
Key words: chronic kidney disease, C-reactive protein, interleukin-6, interleukin-10, hemodialysis, nutritional assessment, tumour
necrosis factor alpha, omega-3 fatty acids, supplementation.
Résumé : La maladie du rein chronique (« CKD ») est un problème de santé publique de plus en plus courant qui augmente de 2 à
3 fois, chez les patients aux prises avec cette maladie, le risque de décès dû aux complications cardiovasculaires comparative-
ment à la population générale. Cette recherche est une étude prospective, randomisée, en double insu chez des patients atteints
de CKD subissant une hémodialyse. Les participants sont répartis dans l’un des deux groupes: le groupe d’étude (groupe A,
46 patients) reçoit quatre capsules (2,4 g) d’acides gras oméga-3 par jour au cours de l’intervention de 12 semaines et les patients
du groupe témoin (groupe B, 47 patients) reçoivent quatre capsules d’huile de paraffine. Les caractéristiques générales des
patients, les indicateurs nutritionnels, les marqueurs des maladies rénales et les marqueurs inflammatoires (protéine C-réactive,
interleukine (« IL »-6, IL-10 et facteur de nécrose tumorale alpha (« TNF- ») sont évalués. Aucune différence n’est observée entre
les caractéristiques générales des patients (P < 0,05) et aucune différence n’apparait dans les indicateurs nutritionnels et les
marqueurs de la maladie rénale (P < 0,05). Après 12 semaines de supplémentation, les patients du groupe A présentent une
diminution significative des niveaux de protéine C-réactive, d’IL-6, de TNF- et du ratio IL-10/IL-6 (P < 0,05). Les patients du groupe
B ne présentent aucun changement significatif des concentrations de marqueurs inflammatoires pendant l’intervention
(P < 0,05). En conclusion, une supplémentation orale en acides gras oméga-3 produit une diminution significative des concen-
trations de marqueurs de l’inflammation chez les patients atteints d’une maladie du rein chronique et sous hémodialyse.
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• La supplémentation orale en acides gras oméga-3 suscite une diminution significative des concentrations de marqueurs de
l’inflammation.
• Cette supplémentation pourrait être administrée aux patients atteints de syndrome urémique et de maladie coronarienne
pour réduire le risque cardiovasculaire.
Mots-clés : maladie du rein chronique, protéine C-réactive, interleukine-6, interleukine-10, hémodialyse, évaluation nutritionnelle,
facteur de nécrose tumorale alpha, acides gras oméga-3, supplémentation.
Introduction
Chronic kidney disease (CKD) is an increasingly common public
health problem that increases the risk of death from cardiovascu-
lar diseases by 2–3 times compared with the general population.
This is because the inflammatory response, mediated by cyto-
kines, chemokines, and other molecules, leads to increased oxi-
dative stress and tissue damage, resulting in an increased risk of
cardiac mortality (Wakasugi et al. 2016). Patients with kidney dis-
ease undergoing hemodialysis have an even higher risk of mortal-
ity (Sabry et al. 2014). Chronic inflammatory status can be assessed
by determining the concentrations of various serum biomarkers,
such as C-reactive protein (CRP), interleukin (IL)-6, IL-10, and tu-
mour necrosis factor alpha (TNF-) (Krintus et al. 2014). These
markers allow an estimation of the severity of inflammation and
the therapeutic response in patients with CKD undergoing hemo-
dialysis (Calder 2017).
One potential therapy is supplementation with omega-3 long-
chain polyunsaturated fatty acids. Omega-3 fatty acids are mainly
obtained from dietary sources, especially fish oil, and they are an
important component of a healthy diet. They may also have ther-
apeutic utility in patients at high risk of inflammatory and cardio-
vascular diseases (Abdelhamid et al. 2018) since they can modify
several risk conditions; specifically, they can modify the athero-
genic risk profile and decrease arterial hypertension, oxidative
stress, and inflammation (Hall 2017). This may be due to their
ability to act in multiple key biological processes, such as eico-
sanoid production, cell membrane physiology, metabolic path-
way signalling, and expression/regulation of the activity of several
genes (Watkins et al. 2016).
Various studies indicate that patients with CKD have signifi-
cantly lower blood levels of omega-3 fatty acids than the general
population, probably because of lower food intake as well as to
inflammation, nutrient malabsorption, and metabolic changes
(Rasic-Milutinovic et al. 2007). Moreover, hemodialysis can affect
the bioavailability of omega-3 fatty acids, since patients undergo-
ing hemodialysis may have increased oxidative stress, which re-
duces concentrations of omega-3 fatty acids (Rivara et al. 2015).
However, another report states that the effects of supplementa-
tion in patients with CKD are independent of hemodialysis
(Fassett et al. 2010).
Despite its potential for the treatment of various pathologies
mediated by inflammation, omega-3 fatty acid supplementation is
not routinely used in patients with CKD, possibly because of igno-
rance of its possible therapeutic effects. Yet in recent decades,
there has been a growing scientific interest in the potential ben-
efits of supplementation with these fatty acids, and several clini-
cal trials have investigated the effects in patients with CKD
undergoing hemodialysis. Some of these studies have shown that
oral supplementation with omega-3 fatty acids lowers the concen-
trations of IL-6, TNF-, and CRP in patients undergoing hemodial-
ysis (Ewers et al. 2009), while other researchers have not found
any significant effects on these markers in similar groups of pa-
tients (Hassan et al. 2010). In view of this contradiction, the objec-
tive of this investigation is to establish the effects of oral omega-3
fatty acid supplementation on inflammation markers in patients
with CKD on hemodialysis.
Materials and methods
Study design and population
This study was prospective, randomized, double-blinded, and
placebo-controlled with 2 parallel arms in adult patients diag-
nosed with CKD and undergoing hemodialysis. All participants
were selected from patients treated in the nephrology office of the
Central and University Hospitals in Maracaibo, Venezuela, during
the period from January 2018 to June 2019. The ethics committee
of the hospital approved the study protocol and consent was ob-
tained in writing from each participant after informing them of
the research objectives in relation to the effect of omega-3 fatty
acid supplementation on inflammatory markers. The study was
registered in the Registry of Clinical Studies (registration no. 2019-
001-0053).
Patient inclusion criteria were glomerular filtration rate
<10 mL/(min·1.73 m2), age over 18 years, body mass index (BMI) of
20–30 kg/m2, regular hemodialysis in the 6 months prior to the
beginning of the study, and willingness to take part in the re-
search. All selected participants had hemodialysis sessions lasting
3–4 h, three times a week, with a low flow dialyzer and using
sodium bicarbonate as a buffer. The hemodialysis procedure re-
mained unchanged during the study period.
Patients with active inflammatory/infectious disease, a history
of peritoneal dialysis, a diagnosis of malignant tumours, chronic
obstructive pulmonary disease, hyperthyroidism, hemoglobinop-
athies, coagulopathies, malabsorption syndrome, surgeries in the
last 6 months, or noncompliance with the hemodialysis program
were excluded. In addition, patients who consumed anticoagu-
lant, lipid-lowering, beta-blocker, L-carnitine, corticosteroid, im-
munosuppressive, and/or immunomodulatory drugs as well as
those with evidence of regular consumption of antioxidant vita-
mins foods rich in omega-3 fatty acids and/or fish oil 6 months
prior to the start of the study, a hypersensitivity/intolerance to
fish products, or noncompliance with the treatment (consump-
tion of less than 70% of the supplement) were also excluded.
The sample size was calculated according to the CRP values
(Iqbal et al. 2015). According to a previous study conducted in
patients with CKD on hemodialysis, a difference of 4 mg/L was
found between the groups, with a standard deviation of 2 mg/mL.
Based on this information, the minimum sample size for each
group was 45 participants, with an estimated power of 80% and
 = 0.05 to detect a 15% change in concentrations. Considering the
possibility of dropouts and exclusions, the size for each group was
established as 56 eligible patients. Participants remained in their
assigned treatment groups regardless of postassignment with-
drawal.
A list of computer-generated random numbers was used in a
block randomization scheme to ensure 2 randomly selected par-
ticipant groups of similar sizes. The numbers were stored in
sealed envelopes and numbered by independent staff. Partici-
pants in the study group (group A) received 4 capsules of omega-3
fatty acids daily during the 12 weeks of intervention. Each capsule
contained 360 mg of eicosapentaenoic acid and 240 mg of doco-
sahexaenoic acid. This omega-3 dose was administered according
to accepted international standards (Bossola et al. 2013). Patients
in the control group (group B) received 4 capsules containing
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paraffin oil. These contained the standard ingredients of soft gel-
atin capsules (gelatin, water, glycerin, and vitamin E in minute
amounts as a preservative). An analysis of the capsules, which
were provided by an independent laboratory, is presented in
Table 1. The appearance (shape, size, and colour) of the capsules
used in both groups was identical. The capsules were divided by
groups, placed in sealed envelopes by a person who was indepen-
dent to the study, and delivered once a week following one of the
hemodialysis sessions. Throughout the study, all participants,
treating doctors, and researchers were unaware of the patients’
group assignments.
Assessment of patients’ functional states
The clinical, biochemical, and functional status data for each
participant were obtained at the beginning of the study and after
the 12 weeks of intervention. The usual diet of each patient was
evaluated using a single 72-h reminder interview and then ana-
lyzed by 2 nutritionists, who were part of the research team but
did not know which treatment group each subject belonged to,
using the Food Processing and Nutrition Analysis Program (Esha
Research, USA). The participants were found to have a low con-
sumption of soy foods, a once-weekly fish intake, and no dietary
supplement of oil rich in long-chain fatty acids. The participants
were asked to continue with their normal eating habits (35 kcal/kg
body weight, protein intake 1.0–1.2 g/kg body weight, and fat <35% of
caloric intake with a sodium restriction of 60–100 mEq/day and a
potassium restriction of 50–100 mEq/day) according to the Clinical
Practice Guidelines K-DOQI, the pharmacological regime, and
their physical activity (less than 1 h per week) during the study
period. For all participants, functional evaluations were con-
ducted on a regular basis by means of interviews during hemodi-
alysis sessions. Antihypertensive treatment was used to maintain
blood pressure values of less than 160/90 mm Hg.
Patients’ weight was measured with an approximation of 0.1 kg
using a calibrated electronic digital scale while patients were
barefoot and wearing light clothing. Height was measured with
an accuracy of 0.1 cm, using a portable stadiometer that had a
nonelastic tape and was mounted to the wall, while patients were
barefoot with heels touching the ground and eyes directed for-
ward. Both measurements were made in the 20 min following the
end of the hemodialysis session and always by the same duly
trained person. The average of 3 successive measurements of body
weight before the start and end of the study period was used to
assess body weight. BMI was calculated and expressed as kg/m2.
The quality of dialysis was measured for each subject before and
after the study period according to serum urea nitrogen concen-
trations before and after dialysis, ultrafiltration volume, dialysis
time, and weight after dialysis using the equation of Leypoldt
et al. (2004).
Compliance with supplementation was evaluated twice a week
by one of the researchers who was unaware of the randomization
of the participants and using the conventional practice of “pill
counting”, based on the known number of capsules given to the
patient at their last interview and the counted number of unused
capsules that the patient returned to the clinic. An intake exceed-
ing 70% of the prescribed capsules during the study period was
considered to be adequate compliance. Any change in medica-
tions during the study period was recorded.
Biochemical tests and trials
Blood samples (20 mL) were taken from each patient before and
after the 12 weeks of interventionandwereobtainedaftera 12-hnight
fast and immediately before the hemodialysis session. The sam-
ples were stored in sterile tubes containing EDTA to separate the
serum. All samples were centrifuged immediately at 3500 rpm
(RCF = 5000) for 10 min. The serum was then separated, divided
into aliquots, and subsequently stored at –70 °C for subsequent
determination of inflammatory markers. CRP concentrations
were determined by a turbidimetric method with intra- and
inter-assay variability coefficients of 8% and 9%, respectively
(Diagnostics Biochem Canada Inc., London, Ont., Canada). The
concentrations of IL-6, TNF-, and IL-10 were measured in du-
plicate with immunoassays (Immunotech, Beckman Coulter,
USA). These measurements had intra- and inter-assay variability
coefficients of 8% and 10%, respectively. Functional status was
evaluated by determining serum albumin concentrations using
the green colorimetric method of bromocresol (Autoanalyzer
BT3000, Biotechnica, Italy). Routine tests for the follow-up of he-
modialysis patients (creatinine, urea, urea nitrogen, uric acid, he-
moglobin, glucose, phosphorus, calcium, potassium, and sodium)
were also conducted on these samples at the beginning and end of
the study in the hospital laboratory according to automated stan-
dard procedures.
Statistical analysis
The data were analyzed using a statistical program for social
sciences, SPSS Statistics for Windows version 22 (IBM Corp.,
Armonk, N.Y., USA). The categorical data were presented as abso-
lute values and percentages, while the continuous data were pre-
sented as means and SD. All quantitative data were analyzed to
determine normality using the Kolmogrov–Smirnov test and the
Shapiro–Wilk test. A t test was used for related samples and the
Mann–Whitney test was used to determine the differences in
the variables of interest between the 2 groups at the beginning
and at the end of the study. Fischer’s exact test was used to com-
pare the categorical variables between both groups. Differences in
quantitative variables between the groups were analyzed using
the t test for unrelated samples or the Kruskal–Wallis test during
the 12-week intervention period. The value of P ≤ 0.05 was consid-
ered statistically significant.
The study was conducted according to the World Medical Asso-
ciation’s Declaration of Helsinki. The patients gave their written in-
formed consent, and this consent and the study protocol were
approved by approved by the Venezuelan committee on human
research in Maracaibo (the Comité de Ética en Investigación of the
Ministerio del Poder Popular para la Salud).
Results
A total of 124 patients were selected for the investigation, of
which 102 were eligible to take part in the trial. After randomiza-
tion, 19 patients (10 in group A and 9 in group B) were excluded
from the final analysis because of losses during follow-up, which
Table 1. Composition of fatty acids of the omega-3 and placebo
capsules.
Omega-3 capsules,
g/100 g as fatty acids
Placebo capsules,














C22: 6n3 24.31 —
Saturated fatty acids 7.02 17.26
Monounsaturated fatty acids 15.21 70.63
Polyunsaturated fatty acids 77.77 12.11
Omega-3 67.08 0.69
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included death, withdrawal for personal reasons, change of dial-
ysis centre, and a lack of provided information or lack of re-
sponses to questions about compliance with the treatment. The
flowchart of patient participation during the study is presented in
Fig. 1. Therefore, for the final analysis, the data of the 46 patients
assigned to be treated with omega-3 fatty acids (group A) and the
47 patients assigned to the control group (group B) were used.
Table 2 shows the general characteristics of the patients in both
groups. The mean (SD) age of the patients in group A was 52.1 (8.2)
years and in group B it was 49.6 (8.3) years. The differences be-
tween the groups were not significant (P = 0.15). Most patients in
both treatment groups were male (65.2% in group A and 68.1% in
group B). No significant difference was found between the groups
in relation to the frequency by sex (P = 0.83). The BMI and the
average duration of hemodialysis were also similar in both study
groups (P = 0.21 and P = 0.57, respectively). Furthermore, no sig-
nificant differences were found between the groups in the fre-
quency of history of dyslipidemia, statin use, hypertension,
diabetes, smoking, and use of erythropoietin (P ≥ 0.05).
Table 3 shows the functional indicators and disease markers for
each of the groups before and after treatment. In group A, no
significant differences were observed in the body mass index and
hemodialysis quality before and after the 12 weeks of treatment
with omega-3 fatty acids (P = 0.36 and P = 0.32). Also, no significant
differences were found in the values of hemoglobin, albumin,
creatinine, urea, uric acid, sodium, glycemia, potassium, phos-
phorus, and calcium during the study period (P ≥ 0.05). The pa-
tients in group B also showed no differences in these functional
indicators or in markers of renal disease after the study period
compared with their initial values (P ≥ 0.05). These differences in
indicators and markers between both study groups after 12 weeks
of treatment were considered not significant (P ≥ 0.05).
When analyzing the variations in the concentrations of inflam-
matory markers in both groups of patients (Table 4), a significant
decrease in CRP concentrations (–26.08%) was observed during
the 12 weeks of oral supplementation with omega-3 fatty acids
(P ≤ 0.001). This finding was accompanied by decreases in the
concentrations of IL-6 (–25.06%) and TNF- (–13.13%). Both de-
creases were considered statistically significant (P ≤ 0.001 and
P = 0.009, respectively). IL-10 concentrations also increased during
the 12-week intervention period (+12.21%); however, this change
was not considered significant (P = 0.27). On the other hand, the
IL-10/IL-6 ratio increased significantly (+41.65%; P ≤ 0.001), and
while the IL-10/TNF- ratio increased (+16.08%), it was not signifi-
cant (P = 0.12). In the patients of group B, no differences were
found in the final values compared with the initial values of the
inflammation markers (P ≥ 0.05). Overall, statistically significant
differences between group A and group B were observed in the
markers of inflammation and in the relationships between the
interleukins (P ≤ 0.05) after 12 weeks of treatment.
Discussion
The research results clearly show that oral omega-3 supplemen-
tation causes a decrease in the concentrations of CRP, IL-6, and
TNF- in patients with CKD on hemodialysis. In addition, serum
IL-10 concentrations showed significant variations related to the
comparison of both study groups (patients receiving supplements
and the control group), but no significant differences were found
within them. These findings suggest that omega-3 fatty acids ex-
erted a beneficial effect through the reduction of inflammation
markers in this group of patients.
Inflammation is a common characteristic of patients with CKD,
whether undergoing hemodialysis or not. High concentrations of
inflammation markers enhance oxidative stress, which leads to
increased cardiovascular risk (Dai et al. 2017). There is evidence
that the progress of CKD is associated with low-grade inflamma-
tion, even in patients with moderate renal impairment who are
not undergoing hemodialysis. This suggests that increased con-
centrations of CRP, IL-6, and TNF- are related to the severity of
the disease (Memoli et al. 2002). Some researchers have shown
that low concentrations of inflammatory markers improve sur-
vival in patients with CKD (Memoli et al. 2010; Šulović 2017).
Therefore, the modulation of inflammation in these patients can
slow the progression of the disease.
Previous investigations, both in vitro and in vivo, have shown
that omega-3 fatty acids can modify different aspects of the in-
flammation process (Moertl et al. 2011). The mechanism by which





• Not eligible (n = 17)
• Decided not to participate (n = 4) 
• Other reasons (n = 1)
Selected for randomization (n = 102)
GROUP A (Omega - 3)
Selected for intervention (n = 56)
• They completed the selection criteria (n = 54)
• Not completing the selection criteria (n = 2)
GROUP B (Controls)
Selected for intervention (n = 56)
• Complete the selection criteria (n = 55)
• Not completing the selection criteria (n = 1)
Losses during follow-up (n = 3)
Death during treatment (n = 1)
Withdrawal for personal reasons (n = 1)
Losses during follow-up (n = 2)
Dialysis center change (n = 2)
Withdrawal for personal reasons (n = 1)
Analyzed (n = 46)
• Excluded from the analysis (n = 2)
* Lack of information (n = 1)
* Doubts about compliance with 
treatment (n = 1)
Analyzed (n = 47)
• Excluded from the analysis (n = 3)
* Lack of information (n = 2)
* Doubts about compliance with       




Table 2. General characteristics of both patient groups.
Group A
cases, n = 46
Group B
control, n = 47 P
Age, y 52.1 (8.2) 49.6 (8.3) 0.15
Sex, n (%)
Male 30 (65.2) 32 (68.1) 0.83
Female 16 (34.8) 15 (31.9)
Body mass index, kg/m2 21.1 (1.8) 21.6 (2.0) 0.21
Hemodialysis time, mo 56.5 (17.8) 54.6 (14.5) 0.57
History of dyslipidemia, n (%) 34 (73.9) 33 (70.2) 0.82
History of statin use, n (%) 24 (52.1) 21 (44.7) 0.54
History of hypertension, n (%) 22 (47.8) 17 (36.2) 0.30
History of diabetes, n (%) 17 (36.9) 13 (27.7) 0.38
History of smoking habit, n (%) 5 (10.8) 6 (12.8) 10.00
Erythropoietin use, n (%) 44 (95.7) 41 (87.2) 0.26
Note: Values are means (SD) unless otherwise specified.
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they exert their anti-inflammatory effects can be through protein
kinase, activated by AMPk through a protein called silent infor-
mation regulator 1, which leads to the deacetylation of the nu-
clear factor kappa B (NF-B), is stimulated by proinflammatory
agents such as cytokines and CRP. The activation of NF-B and
mononuclear cells triggers a process that culminates with myo-
cardial inflammatory damage in patients undergoing hemodialy-
sis (Wang et al. 2017). It has also been shown that arachidonic acid
can be competitively inhibited by decreasing the conversion of
proinflammatory intermediates (Inoue et al. 2017). In addition,
because the fatty acids present in the cell membrane play an
important role in signal transduction, omega-3 fatty acids can
modify gene expression (Calder 2015).
This study contributes to a body of existing research that has
found potential therapeutic benefits to omega-3 supplementation
for CKD patients on dialysis through the reduction of inflamma-
tion. Several of these previous studies have described results such
as the attenuation of dyslipidemia and inflammation (decreased
CRP and IL-6 concentrations). Others have found that omega-3
fatty acids produce a significant decrease in CRP concentrations in
Cree adults (aged 18–91 years) (Labonte et al. 2014). It has also been
shown that omega-3 fatty acids decrease inflammatory markers
concentrations in patients with both chronic diseases and dia-
betic neuropathy (Han et al. 2016). A study examining oral supple-
mentation with 1.3 g/day of omega-3 fatty acids daily for 3 months
found a decrease in CRP concentrations (Saifullah et al. 2007). An
investigation in patients with CKD and hemodialysis treated with
3 g/day of omega-3 fatty acids for 3 months showed a significant
reduction in CRP and IL-6 concentrations (Tayyebi-Khosroshahi
et al. 2012). Another study that used 1800 mg/day for 4 months
reported a significant reduction in CRP and IL-6 concentrations
(Gharekhani et al. 2014).
In contrast with the findings of this study, other papers have
failed to show a reduction in inflammation by supplementing
omega-3 for CKD patients. Besides, in 1 study, using a dose of
2.08 g/day for 10 weeks found no decrease in concentrations of
systemic inflammatory and oxidative stress markers (Kooshki
et al. 2011). However, other research has not shown that omega-3
fatty acids have a significant effect on inflammatory markers in
patients with CKD (Hassan et al. 2010). On the other hand, in
another study that evaluated the effects of omega-3 fatty acids
(3.4 g/day for 1 year) in patients receiving heart transplants, the
patients in the treatment group presented increased concentra-
tions of TNF- and decreased concentrations of IL-10, suggesting
a pro-inflammatory effect (Holm et al. 2001).
This investigation also contributes to a body of work reporting that
omega-3 fatty acid supplementation reduces TNF- concentrations sig-
nificantly in patients undergoing hemodialysis (Tayyebi-Khosroshahi
et al. 2012). For example, in a study that used 2.4 g/day supplementation
for 8 weeks in patients with CKD and hemodialysis, a significant
decrease in TNF-, IL-6, CRP, and ferritin concentrations was ob-
served (Leypoldt et al. 2004). It is possible for omega-3 to produce
these results because they are a type of polyunsaturated fatty
acids that can also decrease the production of classic proinflam-
matory cytokines as well as adhesion molecules involved in the
inflammatory response. A significant increase in the values of the
IL-10/IL-6 ratio compared with a placebo was also observed in this
study. Therefore, omega-3 fatty acid supplementation acts as pro-
tection against the negative effects of IL-6 and TNF- (Magee et al.
2012).
The afore mentioned contradictory results of previous studies
evaluating the effects of omega-3 fatty acid supplementation on
inflammation markers in patients with CKD may arise from sev-
eral different factors. Possible explanations for the differences
observed include duration of treatment, sample size, and the ref-
erence values of inflammatory markers. In addition, the dose and
duration of supplementation should be considered, since higher
doses over a longer period could decrease the concentrations of
CRP, IL-6, TNF-, and other inflammatory markers in patients
with CKD who are undergoing hemodialysis on a regular basis
(Fiedler et al. 2005). Another consideration would be related to the
background of the selected patients in each study, which may
Table 3. Variations of the functional indicators and markers of kidney disease between groups before and after treatment.
Average ± SD
Group A cases (n = 46) Group B control (n = 47)














Body mass index, kg/m2 21.1 (1.8) 21.5 (2.0) 1.89 0.36 21.8 (2.0) 21.1 (2.0) 3.21 0.93 0.34
Hemodialysis quality, kt/v 1.46 (0.14) 1.43 (0.15) 2.05 0.32 1.42 (0.13) 1.44 (0.14) 1.44 0.48 0.74
Hemoglobin, g/dL 10.1 (1.2) 9.9 (1.1) 1.98 0.41 9.9 (1.1) 10.2 (1.0) 3.03 0.17 0.17
Albumin, g/dL 4.00 (0.20) 3.98 (0.23) 0.50 0.66 4.03 (0.23) 3.96 (0.32) 1.73 0.23 0.68
Creatinine, mg/dL 10.1 (2.3) 10.0 (2.2) 1.00 0.83 9.6 (2.3) 10.3 (2.3) 7.29 0.14 0.52
Urea, mg/dL 1.38 (0.20) 1.39 (0.23) 0.72 0.82 1.38 (0.17) 1.41 (0.21) 2.17 0.45 0.66
Uric acid, mg/dL 5.83 (0.64) 6.06 (0.61) 3.94 0.08 5.87 (0.67) 6.00 (0.68) 2.21 0.35 0.66
Glycemia, mg/dL 101.3 (25.2) 96.8 (22.6) 4.44 0.37 100.2 (25.8) 101.3 (25.6) 1.09 0.84 0.37
Sodium, mEq/L 131.9 (1.2) 131.8 (1.3) 0.7 0.70 131.8 (1.1) 132.1 (1.0) 0.22 0.17 0.22
Potassium, mEq/L 5.5 (0.3) 5.4 (0.4) 1.81 0.18 5.4 (0.4) 5.5 (0.3) 1.85 0.17 0.18
Phosphorus, mEq/L 8.70 (0.30) 8.59 (0.29) 1.26 0.08 8.68 (0.29) 8.70 (0.22) 0.8 0.19 0.06
Calcium, mEq/L 4.2 (0.4) 4.1 (0.5) 2.38 0.29 4.1 (0.3) 4.2 (0.4) 2.43 0.17 0.29
Note: Values are means (SD). kt/v, quality of dialysis.
Table 4. Variations in the concentrations of inflammation markers before and after treatment.
Average ± SD
Group A cases, n = 46 Group B control, n = 47














C-Reactive protein, mg/L 14.9 (3.1) 10.9 (2.8) 26.8 <0.001 15.4 (3.1) 15.6 (3.2) 1.29 0.76 <0.001
IL-6, mg/mL 72.9 (24.4) 53.9 (14.9) 25.06 <0.001 71.1 (26.1) 68.8 (25.4) 3.23 0.67 <0.001
TNF-, mg/mL 67.0 (13.9) 58.2 (12.4) 13.13 0.002 69.4 (14.3) 69.1 (14.9) 0.43 0.93 <0.001
IL-10, pg/mL 117.9 (42.1) 132.3 (47.0) 12.21 0.27 114.7 (37.6) 112.1 (38.9) 0.55 0.74 0.03
Relationship IL-10/IL-6 1.80 (0.87) 2.55 (1.13) 41.65 <0.001 1.89 (1.08) 1.95 (1.16) 4.27 0.80 0.01
IL-10 ratio/TNF- 1.99 (0.83) 2.31 (1.11) 16.08 0.12 1.73 (0.69) 1.72 (0.83) 0.57 0.95 0.005
Note: Values are means (SD). IL, interleukin; TNF-, tumor necrosis factor alpha.
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alter the results of the investigations. Finally, the duration and
severity of inflammation should also be taken into account, espe-
cially in those patients undergoing hemodialysis.
In this investigation, serum albumin concentrations, one of the
markers of functional status, showed no changes during the treat-
ment period in the group of patients treated with omega-3 fatty
acids, which is similar to previously reported results (Sarav and
Friedman 2018). Reduced protein intake and increased inflamma-
tory response are 2 important factors that lead to a decrease in
serum albumin (Barle et al. 2006). In addition, one previous study
showed that low serum albumin concentrations in dialysis pa-
tients may be caused by systemic inflammation rather than nutri-
tional insufficiency. Other authors suggest that serum albumin
should be considered as a marker of disease rather than nutrition
(Donadio et al. 2012). BMI, dialysis efficiency, and markers of kid-
ney disease also showed no change during the treatment period in
this study, either when comparing the values before and after
treatment or when comparing the final values of the groups of
cases and controls. Similar results have been previously reported
(Svensson et al. 2008; Tayyebi-Khosroshahi et al. 2012).
In summary, the results of this investigation point to the conclu-
sion that oral supplementation of omega-3 fatty acids produces sig-
nificant decreases in the concentrations of inflammation markers in
patients with CKD on hemodialysis. Since previous studies on the
beneficial effect of omega-3 fatty acid supplementation on cardio-
vascular risk are contradictory, the present study is extremely
important in underlining this positive effect. Thanks to the data
provided in this work, we are able to demonstrate that including
natural sources or supplements with omega-3 fatty acids in the
regular diets of patients with CKD could improve their general
condition. Therefore, it is essential that omega-3 supplementation
become part of the regular protocol of dietary therapy in patients
with CKD to improve their quality of life and reduce death rates.
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